NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...
Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABA A α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuroscience portfolio with...
MIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization...
Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The global biologics industry is experiencing unprecedented expansion as the market surges toward $679.56...
Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growth AUVELITY ® 3Q 2025 net product sales of $136.1 million, representing 69% year-over-year growth ...
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...
UBS analyst Ashwani Verma maintained a Buy rating on Axsome Therapeutics today and set a price target of $163.00. The company’s shares closed yesterday at $129.58.Elevate Your Investing Strategy: Take...
In a report released on October 7, Marc Goodman from Leerink Partners maintained a Buy rating on Axsome Therapeutics. The company’s shares closed yesterday at $122.52.Elevate Your Investing Strategy:...